Gregor James MacDonald

This inventor holds 56 USPTO granted patents and 13 published patent applications and 39 EPO patents, primarily in Pharmaceutical Chemistry (CPC class A61K). Top assignees: Janssen Pharmaceutica Nv, Janssen Pharmaceuticals, Inc., Addex Pharma, S.a.. Active years: 2012-2021.

USPTO Granted Patents = 56 (Patent Applications = 13)

% Patents Active = 42.9

EPO Patents = 39 (Patent Applications = 41)

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 163(Granted Patents)

Forward Citations (Not Self Cited) = 109(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Emblem, BE (2015)
Ranst, BE (2016)
Zoersel, BE (2012 - 2020)
Beerse, BE (2012 - 2021)

Company Filing History:

25 out of 2,099

Janssen Pharmaceutica Nv

patents

25 out of 161

Janssen Pharmaceuticals, Inc.

Vanderbilt University

Addex Pharmaceuticals S.a.

patents

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

Areas of Expertise:

Dopamine Receptor Antagonists

mGluR Modulators

Allosteric Modulators

Neuropsychiatric Disorders

Thiazole Derivatives

Pyridine Derivatives

Pyrazole Analogues

Beta-Secretase Inhibitors

Serotonin Receptor Modulators

Bicyclic Compounds

Triazole Derivatives

Heterocyclic Compounds

56 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11071729 - 1',3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones (2021-07-27),

2. 10584129 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2020-03-10),

3. 10106542 - Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors (2018-10-23),

4. 9828350 - 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) (2017-11-28),

5. 9751860 - Piperidin-4YL-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists (2017-09-05),

6. 9737533 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2017-08-22),

7. 9468640 - Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists (2016-10-18),

8. 9422296 - Fast-dissociating dopamine 2 receptor antagonists (2016-08-23),

9. 9388175 - 2-aniline-4-aryl substituted thiazole derivatives (2016-07-12),

10. 9271967 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors (2016-03-01),

11. 9266834 - 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors (2016-02-23),

12. 9226930 - 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2016-01-05),

13. 9181245 - Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease (2015-11-10),

14. 9174953 - Bicyclic thiazoles as allosteric modulators of mGluR5 receptors (2015-11-03),

15. 9132122 - [object Object] (2015-09-15),

Dear valued reader, I am pleased to present to you an article focusing on the remarkable inventor Gregor James MacDonald, whose groundbreaking innovations have deeply influenced the field of pharmaceuticals.

Title: Gregor James MacDonald: Pioneering Innovations in Pharmaceutical Science

Introduction:

Gregor James MacDonald, a distinguished inventor based in Beerse, Belgium, has made significant contributions to the realm of pharmacology through his inventive creations.

Latest Patents:

With an impressive portfolio of 53 patents to his name, Gregor's latest inventions include compounds such as 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones and substituted 6,7-dihydropyrazolo[1,5-a]pyrazines, showcasing his expertise in developing treatments for neurological and psychiatric disorders.

Career Highlights:

Having worked extensively with renowned companies like Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica Nv, Gregor has honed his skills in research and development, leading to the creation of innovative pharmaceutical solutions that have the potential to revolutionize healthcare.

Collaborations:

Throughout his career, Gregor has collaborated with esteemed professionals in the field, including his coworkers Jose Maria Cid-Nunez and Andres Avelino Trabanco-Suarez, collectively driving forward advancements in pharmaceutical science.

Conclusion:

In conclusion, Gregor James MacDonald stands as a testament to the power of innovation and the impact that one individual can have on shaping the future through their inventive spirit. His dedication to developing novel compounds for the treatment of complex disorders underscores his commitment to improving the quality of life for individuals around the world.